The present meta-analysis was conducted to establish a correlation between circulating or tissue IL-8 and clinical RCC outcomes, defined as overall survival (OS, primary endpoint) and progression-free survival (PFS, secondary endpoint) by evaluating published clinical studies on this topic, available as of June 2024. This evidence concerns the gene CXCL8 and renal cell carcinoma.